Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by Stormdog01on Apr 03, 2020 1:09pm
141 Views
Post# 30876403

RE:That Jan D'alvise is quite the manager

RE:That Jan D'alvise is quite the managerShe is paid half a million per year + 1.3M stock options to manage a +-20 employee company from her home in Dan Diego. And some supposedly 'top-compensation firm' still believe she is paid much less than what she should be paid.

Let's just think about it for 2 minutes... 500K/yr.... working remotely from your basement... Plus the stock options...

''In terms of management and board compensation, the board, completely independent of management, brought in one of the top compensation firms in the life science industry, and they assembled a peer group compensation data set for benchmarking purposes.  That analysis showed that our management and the board are well below market in terms of cash compensation and stock options held.''

Ok so basically the BOARD hires an 'independant' firm to do the assessment of management comp AND the assessment of the BOARD comp....Do you think that if the 'independant' firm gives them numbers that seem too reasonably low (especially for the board), they will be re-hired for the next year?

Board wants more comp for them and management (since changing management is a pain in the a** for any board), pays big bucks to a firm to get independant report. Firm wants big bucks every year from the company, gives highest numbers possible to keep them happy. Rinse and repeat.

I would pay 100$ so see the whole comp report with the peer comparisons they've chosen, and the performance scorecard they gave to each of the management team.

Hint: Not sure there are that many peers being CEO working from home, managing an about 20 employees company, with a total phase 3 failure due to bad protocol/execution. I wonder where they actually found the comparisons. I will also make no commentary on that Groch guy on the payroll, paid 300K+ per year plus stock options. Just see for yourselves:

Groch job description: sign commercial deals.
Groch deals signed so far: 0.
Groch paycheck so far: About 700K in cash + over 1M stock options



Bullboard Posts